Now showing items 1-1 of 1

    • Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. 

      Torres, Vicente.; Chapman, Arlene.; Devuyst, Oliver.; Gansevoort, Ron.; Perrone, Ronald.; Koch, Gary.; Martin, Rodolfo.; et al. (Massachusetts Medical Society, 2017-11-16)
      BACKGROUND: In a previous trial involving patients with early autosomal dominant polycystic kidney disease (ADPKD; estimated creatinine clearance, ≥60 ml per minute), the vasopressin V2-receptor antagonist tolvaptan slowed ...